Company News 24 Jul 2024 Orthocell Accelerates Global Market Expansion of Striate+â„¢ and Remplirâ„¢ With Seven New Regulatory Applications either in progress or planned Orthocell has announced the accelerated market expansion of Striate+â„¢ and Remplirâ„¢, with seven regulatory applications either in progress or planned… Orthocell
Company News 11 Jul 2024 Orthocell Receives Regulatory Approval to Commence Sales of Striate+â„¢ in Canada Orthocell has received a Medical Device Licence from Health Canada, allowing the commencement of sales of its market leading dental… Orthocell
Company News 09 Jul 2024 Orthocell Continues Impressive Growth with Record Quarterly and Yearly Revenue Achieved Orthocell has announced that it has recorded impressive sales growth across its product portfolio, with total revenue for FY24 of $6.72million… Orthocell
Company News, Media 14 Jun 2024 Petra Capital Research Report | June 2024 Petra Capital has released research report, forecasting Orthocell’s potential to reach A$1.28 per share. Orthocell
Company News 11 Jun 2024 Orthocell applies for TGA market approval for SmrtGraftâ„¢ Orthocell has applied to the Therapeutic Good Administration (TGA) for Australian market approval for its SmrtGraftâ„¢ tendon repair device, in… Orthocell
Company News 30 Apr 2024 Remplirâ„¢ nerve repair study published in peer-reviewed clinical journal Orthocell has announced that results from the Remplirâ„¢ nerve regeneration clinical trial have been published in a high profile clinical… Orthocell
Company News 15 Apr 2024 Orthocell receives $3.05m R&D tax incentive refund Orthocell has announced that it has received a Research and Development (R&D) Tax Incentive refund of A$3,051,483 for the financial… Orthocell
Company News 08 Apr 2024 Quarterly Report – Period To 31 March 2024 Orthocell has today published its Quarterly Report for the period ended 31 March 2024. Orthocell
Company News 25 Mar 2024 Orthocell Successfully Completes Surgeries for Remplirâ„¢ US Market Authorisation Orthocell has announced that it has successfully completed the first stage of the Remplirâ„¢ US 510(k) market authorisation nerve repair… Orthocell
Company News 22 Feb 2024 Orthocell Completes $3.5M Strategic Placement Orthocell has today announced that it has completed a Company-led Strategic Placement to raise $3.5 million. Orthocell
